CL
KPTI icon

CSS LLC’s Karyopharm Therapeutics KPTI Stock Holding History

CSS LLC’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-833
Closed -$240K – 727
2020
Q1 		$240K Sell
833
-4,334
-84% -$1.2M 0.02% 403
2019
Q4 		$1.49M Buy
5,167
+1,500
+41% +$325K 0.08% 196
2019
Q3 		$529K Buy
+3,667
New +$497K 0.03% 302

Other funds holding KPTI

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

CSS LLC's KPTI Position: Q4 2022 in Review

CSS LLC sold out of Karyopharm Therapeutics (KPTI) in Q4 2022, closing a stake of 2,209 shares — an estimated $153K sold.

CSS LLC first reported a position in KPTI in Q2 2020 and held it in 5 quarters. The position peaked at $203K in Q2 2020. 154 funds tracked by Wall St. Rank hold KPTI as of Q4 2022.

  • CSS LLC reported no remaining Karyopharm Therapeutics position as of Q4 2022 after selling out during the quarter.
  • CSS LLC sold 2,209 Karyopharm Therapeutics shares in Q4 2022, an estimated $153K.
  • CSS LLC first reported a position in Karyopharm Therapeutics in Q2 2020 and held it in 5 quarters.
  • CSS LLC's Karyopharm Therapeutics position peaked at $203K in Q2 2020.
  • 154 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q4 2022.

Based on CSS LLC's 13F filing for Q4 2022, filed 14 Feb 2023.